Free Trial
NASDAQ:RNAC

Cartesian Therapeutics 8/17/2023 Earnings Report

Cartesian Therapeutics logo
$10.10 -0.34 (-3.26%)
As of 02:25 PM Eastern

Cartesian Therapeutics EPS Results

Actual EPS
-$1.05
Consensus EPS
-$1.35
Beat/Miss
Beat by +$0.30
One Year Ago EPS
N/A

Cartesian Therapeutics Revenue Results

Actual Revenue
$5.25 million
Expected Revenue
$9.90 million
Beat/Miss
Missed by -$4.65 million
YoY Revenue Growth
N/A

Cartesian Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Conference Call Audio

Earnings Conference Call
Cartesian Therapeutics
00:00 / 00:00

Cartesian Therapeutics Earnings Headlines

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities
This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
See More Cartesian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cartesian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your email.

About Cartesian Therapeutics

Cartesian Therapeutics (NASDAQ:RNAC), a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

View Cartesian Therapeutics Profile

More Earnings Resources from MarketBeat